Recent Advances in Obstructive Sleep Apnea (OSA) - ENT Perspective (2024-2026)

1. Pharmacotherapy - The Tirzepatide Breakthrough (SURMOUNT-OSA)

• Two parallel RCTs in adults with moderate-to-severe OSA (mean AHI ~50 events/hour) and obesity (mean BMI ~39)
• Trial 1 (PAP-naive): Tirzepatide reduced AHI by -25.3 events/hour vs. -5.3 with placebo (treatment difference: -20 events/hour; p<0.001)
• Trial 2 (PAP users): Reduction of -29.3 events/hour with tirzepatide vs. -5.5 with placebo (treatment difference: -23.8 events/hour; p<0.001)
• Significant improvements in: body weight, hypoxic burden, hsCRP, systolic blood pressure, and patient-reported sleep outcomes
• Adverse effects were primarily GI (mild-moderate)

2. Hypoglossal Nerve Stimulation (HNS) - Maturing Evidence

Systematic Review and Meta-Analysis (2024)

• Inspire device: AHI reduced by -20.14 events/hour (short-term) and -15.91 events/hour (long-term)
• ODI reduced by -14.16 (short-term), -12.95 (long-term)
• Epworth Sleepiness Scale (ESS) improved by -5.02 (short-term)
• High adherence and patient satisfaction rates
• Conclusion: HNS is safe and effective; selection criteria could be broadened

3-Year RCT Outcomes - Proximal HNS (THN3 Trial)

• 104/138 (75%) completed 3-year follow-up
• Median AHI reductions of -15.1/h to -17.7/h sustained at 24 and 36 months vs. baseline (large effect sizes)
• QOL improvements maintained throughout
• Outcomes were comparable to distal HNS (STAR trial data)
• Favorable safety profile with relatively few adverse events

Network Meta-Analysis - Comparing Electrical Stimulation Modalities

• SMES showed the greatest AHI reduction (SMD = -1.14) and best oxygenation improvement
• TENS significantly improved lowest O2 saturation (LSAT)
• HNS produced the largest improvement in daytime sleepiness (ESS; SMD = -1.03)
• Conclusion: each modality has specific benefits; supports personalized selection

3. Drug-Induced Sleep Endoscopy (DISE) - Expanding Role

DISE for Surgical Outcome Assessment

• Post-surgical DISE using VOTE scoring showed significant reductions at velum and oropharynx after palate surgery, and at velum, oropharynx, and tongue after maxillomandibular advancement (MMA)
• Nasal surgery alone showed no significant changes in VOTE scores at any level
• DISE provides a nuanced, anatomically-specific view of surgical outcomes - a step beyond AHI alone

DISE-Directed Tongue Surgery in Pediatric Persistent OSA

• Post-DISE tongue surgery reduced AHI from 9.5 to 4.2 events/hour (mean difference -5.13; p<0.00001)
• LSAT improved by ~3% (from 87.8% to 90.1%)
• Overall surgical response rate: 70%
• Supports DISE-directed approach as second-line treatment in children

DISE in Pediatric OSA with Trisomy 21

DISE vs. CT for Mandibular Advancement Device (MAD) Prediction

DISE Sedative Agent Standardization

4. Conservative/Non-PAP Alternatives

Positional Therapy vs. CPAP vs. Oral Appliances

• Sleep positional therapy (SPT) significantly reduces AHI in supine position (MD = -7.46) vs. placebo
• SPT is inferior to CPAP in reducing overall AHI and improving oxygenation
• SPT has a lower complication rate than both OAT (OR=0.54) and CPAP (OR=0.29)
• Clinically useful for positional OSA (POSA) patients who are CPAP-intolerant

Oral Appliances

5. Surgical Advances

TORS (Transoral Robotic Surgery) for OSA

• Mean AHI decrease of ~24 events/hour
• Overall surgical "success" (AHI <20 + 50% reduction) with robotic multilevel sleep surgery
• Complication rate ~22% (no life-threatening events)
• Best results when BMI <30

Maxillomandibular Advancement (MMA)

CPAP Mask Type - Nasal vs. Oronasal

6. Updated Guidelines

Chinese Thoracic Society Guidelines 2025

MANTRA Trial (Ongoing, 2026)

Summary Table